Get startedLog in
    Picture of EyePoint logo

    EYPT — EyePoint News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Eyepoint Pharmaceuticals Announces Positive Interim 16-Week Data For Ongoing Phase 2 Verona Clinical Trial Of Duravyu For Diabetic Macular Edema

    Picture of EyePoint logoEyePoint
    28/10/2024 11:55
    Oct 28 (Reuters) - EyePoint Pharmaceuticals Inc
 EYPT.O :
    * EYEPOINT PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM
16-WEEK DATA
FOR ONGOING PHASE 2 VERONA CLINICAL TRIAL OF DURAVYU™ FOR
DIABETIC MACULAR EDEMA
    * EYEPOINT PHARMACEUTICALS INC - FULL TOPLINE DATA EXPECTED
IN Q1
2025
    * EYEPOINT PHARMACEUTICALS INC: FAVORABLE SAFETY PROFILE
CONTINUES
WITH NO DURAVYU-RELATED OCULAR OR SYSTEMIC SAES TO DATE

Source text:  ID:nGNX9TP1v6 
Further company coverage:  EYPT.O 

 ((Reuters.Briefs@thomsonreuters.com))

    Recent news on EyePoint

    See all news